{
  "scenario_id": "biotechnology_gene_editing_therapeutic_trials_decision",
  "context": "Biotechnology company developing CRISPR-based gene editing therapies for genetic disorders, evaluating clinical trial initiation for lead candidate targeting cystic fibrosis",
  "stakeholders": {
    "requester": "Chief Scientific Officer",
    "approvers": [
      "CEO",
      "Chief Medical Officer",
      "Chief Financial Officer"
    ],
    "influencers": [
      "Head of Regulatory Affairs",
      "VP Clinical Development",
      "Patient Advocacy Group Representative"
    ]
  },
  "request": {
    "amount": "$45,000,000",
    "purpose": "Phase 1/2 clinical trial for CRISPR gene editing therapy",
    "urgency": "high",
    "justification": "Preclinical data shows 85% efficacy in animal models with acceptable safety profile; first-in-class therapy for genetic disease with high unmet medical need"
  },
  "decision_process": [
    {
      "stage": "initial_review",
      "duration": "3 weeks",
      "activities": [
        "Preclinical data review",
        "Regulatory landscape assessment",
        "Competitive analysis",
        "Financial modeling"
      ],
      "outcome": "Advanced to detailed evaluation"
    },
    {
      "stage": "due_diligence",
      "duration": "6 weeks",
      "activities": [
        "Clinical trial design review",
        "Manufacturing scalability assessment",
        "IP protection evaluation",
        "Market access strategy development"
      ],
      "outcome": "Approved with conditions"
    },
    {
      "stage": "final_approval",
      "duration": "2 weeks",
      "activities": [
        "Board presentation",
        "Risk mitigation planning",
        "Budget allocation",
        "Timeline establishment"
      ],
      "outcome": "Approved"
    }
  ],
  "business_impact": {
    "expected_outcome": "First-in-class gene editing therapy for cystic fibrosis, potential $2B+ market opportunity",
    "projected_value": "$500,000,000",
    "risk_factors": [
      "Regulatory approval uncertainty",
      "Manufacturing complexity",
      "IP challenges",
      "Clinical trial safety concerns"
    ]
  },
  "decision_criteria": [
    "Scientific validity of preclinical data",
    "Regulatory pathway clarity",
    "Manufacturing feasibility",
    "Market opportunity assessment",
    "Financial risk profile",
    "Ethical considerations"
  ],
  "outcome": "Approved",
  "lessons_learned": "Comprehensive preclinical validation and regulatory engagement critical for gene editing therapies; early manufacturing process development reduces clinical trial risks"
}